Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 294

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer

Carducci, Michael A., Saad, Fred, Abrahamsson, Per‐Anders, Dearnaley, David P., Schulman, Claude C., North, Scott A., Sleep, Darryl J., Isaacson, Jeffrey D., Nelson, Joel B., for the Atrasentan Phase III Study Group Institutions.·2007·Cancer

Abstract

BACKGROUND.: The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin‐A receptor antagonist, in patients with metastatic hormone‐refractory prostate cancer (HRPC). METHODS.: This multinational, double‐blind, placebo‐controlled trial enrolled 809 men with metastatic HRPC. Patients were randomized 1:1 to receive either atrasentan 10 mg per day or placebo. The primary endpoint was time to disease progression (TTP), which was determined according to radiographic and clinical measures. Analyses of overall survival and changes in biomarkers also were performed. RESULTS.: Atrasentan did not reduce the risk of disease progression relative to placebo (hazards ratio, 0.89; 95% confidence interval, 0.76–1.04; P = .136). Most patients progressed radiographically at the first 12‐week bone scan without concomitant clinical progression. In exploratory analyses, increases from baseline to final bone alkaline phosphatase (BAP) and prostate‐specific antigen (PSA) levels were significantly lower with atrasentan treatment (P < .05 for each). The median time to BAP progression (≥50% increase from nadir) was twice as long with atrasentan treatment (505 days vs 254 days; P < .01). The delay in time to PSA progression did not reach statistical significance. Atrasentan generally was tolerated well, and the most common adverse events associated with treatment were headache, rhinitis, and peripheral edema, reflecting the vasodilatory and fluid‐retention properties of endothelin‐A receptor antagonism. CONCLUSIONS.: Atrasentan did not delay disease progression in men with metastatic HRPC despite evidence of biologic effects on PSA and BAP as markers of disease burden. Cancer 2007. © 2007 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.22996

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 294

Metadata

Authors
Carducci, M. A., Saad, F., Abrahamsson, P., Dearnaley, D. P., Schulman, C. C., North, S. A., Sleep, D. J., Isaacson, J. D., Nelson, J. B., & for the Atrasentan Phase III Study Group Institutions.
Venue
Cancer
Publisher
Wiley
Published
2007-10-18
Volume
110
Issue
9
Pages
1959-1966
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2042692879
Cited by
294
References
1
FWCI
27.86
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer. https://app.cochat.ai/papers/10.1002/cncr.22996
The paper
Carducci, M. A., Saad, F., Abrahamsson, P., Dearnaley, D. P., Schulman, C. C., North, S. A., Sleep, D. J., Isaacson, J. D., Nelson, J. B., & for the Atrasentan Phase III Study Group Institutions. (2007). A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer. Cancer. https://doi.org/10.1002/cncr.22996

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.